Clinical trials: Pharmacodynamics
Advanced Solid Tumor
A Study to Assess a New Medicine Called IPN01195 When Administered Alone in Adults With Advanced Solid Tumours
The purpose of this study is to determine the appropriate dosage, safety and effectiveness of a new study drug IPN01195 in adults with advanced solid tumours. The participants in this study will have advanced solid tumours.
- Trial name
- NCT06833008
- Testing
- IPN01195
- Where
- 13 sites in United States, France and 2 more
- Volunteers
- 42 people
- Sponsor
- Ipsen
Healthy
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Oral Doses of GLPG0634 in Healthy Subjects
The purpose of the study is to evaluate the safety and tolerability of multiple ascending oral doses of GLPG0634 given to healthy subjects for 10 days compared to placebo.
- Trial name
- NCT01419990
- Testing
- GLPG0634
- Where
- Belgium
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Lakefront Biotherapeutics NV
Psoriasis
A Study Assessing the PK, PD, Safety, and Tolerability of SB414 in Psoriasis
The objectives of this study are to assess the pharmacokinetics, pharmacodynamics, safety, and tolerability of SB414 in subjects with mild to moderate plaque psoriasis.
- Trial name
- NCT03445013
- Testing
- SB414 6%, Vehicle
- Where
- 4 sites in United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Novan, Inc.
Healthy
GLPG0492 Pharmacodynamics
GLPG0492 is a selective androgen receptor modulator: the compound should help protect against (or help restore) muscle loss in case of immobilization (e.g.
- Trial name
- NCT01538420
- Testing
- GLPG0492
- Where
- Belgium
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Lakefront Biotherapeutics NV
Colorectal Neoplasms
Study to Determine Safety, Pharmacokinetics, Pharmacodynamics of BAY73-4506 in Combination With mFOLFOX6 or FOLFIRI
This multi-center, open-label, non-randomized, non-placebo-controlled, Phase I study will define the safety profile and tumor response profile of the multi-kinase inhibitor BAY73-4506 as oral treatment in combination with the…
- Trial name
- NCT00934882
- Testing
- Regorafenib (BAY73-4506)
- Where
- 7 sites in Germany
- Volunteers
- 45 people
- Sponsor
- Bayer
Healthy Subject
A Study of STSA-1002 in Healthy Subjects
This study is a Phase Ib, randomized, double-blind, placebo-controlled, multiple dose, dose escalation safety, tolerability,pharmacokinetic and pharmacodynamic study of STSA-1002 injection in healthy subjects.
- Trial name
- NCT05497635
- Testing
- STSA-1002 Injection
- Where
- 2 sites in China
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Staidson (Beijing) Biopharmaceuticals Co., Ltd
Safety, Pharmacokinetics, Pharmacodynamics, Food Effect
Single + Multiple Ascending Dose and Food Effect Study of AZD7986 in Healthy Volunteers, PK, PD and Safety Study
This is a phase I, randomised, single-blind placebo-controlled, 2-part study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics and food effect of single and multiple oral doses of AZD7986 in healthy volunteers
- Trial name
- NCT02303574
- Testing
- AZD7986, oral solution, 1 to 50 mg/mL
- Where
- United Kingdom
- Volunteers
- 89 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy
A Single Dose Study Of PF-06291874 In Healthy Adult Subjects
The primary purpose of this study is to evaluate the safety and tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of PF-06291874 in healthy volunteers.
- Trial name
- NCT01499017
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- Pfizer
Pain
A Phase 1 Dose Escalation Study of VX-993 in Healthy Participants
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of VX-993 at different doses in healthy participants.
- Trial name
- NCT05653323
- Testing
- VX-993
- Where
- United Kingdom
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Vertex Pharmaceuticals Incorporated
Healthy
A Randomized, Double Blind Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986166 in Healthy Subjects
The primary purpose of this study is to determine if single doses of BMS-986166 are safe and well tolerated in healthy male subjects and female subjects of non-childbearing potential.
- Trial name
- NCT02790125
- Testing
- BMS-986166
- Where
- United States
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Type 2 Diabetes Mellitus
Multiple Ascending Dose Study in Healthy Male Subjects and Overweight to Obese Male and Female Type 2 Diabetes Mellitus (T2DM) Patients
Primary Objective: To assess in healthy adult male subjects: The tolerability and safety of 21-day repeated subcutaneous (SC) doses of SAR425899 including two up titration steps.
- Trial name
- NCT02411825
- Testing
- SAR425899, metformin
- Where
- Germany
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Sanofi
Healthy Volunteers, Diabetes Mellitus, Type 2
A Research Study of How Oral Semaglutide Tablets Work in Healthy People Who Are Chinese
This study looks at the way a new medicine tablet called semaglutide moves in and throughout the body over time. It will also look at if the medicine is safe and the body can accept it.
- Trial name
- NCT04016974
- Testing
- Oral semaglutide
- Where
- China
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Gout
A Study to Evaluate ALN-XDH in Healthy Subjects and Patients With Gout
The purpose of this study is to: Part A: Evaluate the safety and tolerability of single ascending doses of ALN-XDH in healthy adult participants Part B: Evaluate the safety, tolerability and efficacy of ALN-XDH as monotherapy in…
- Trial name
- NCT05256810
- Testing
- ALN-XDH
- Where
- United Kingdom
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Alnylam Pharmaceuticals
Leukemia, Myeloid, Acute
A Phase 1, Open Label Study of Intravenous GSK3745417 to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Determine RP2D & Schedule in Participants With Relapsed or Refractory Myeloid Malignancies Including AML and HR MDS
This is a Phase 1, open label, two-part study to determine recommended phase 2 dose (RP2D) and schedule of GSK3745417 administration in participants with relapsed/refractory AML or HR-MDS.
- Trial name
- NCT05424380
- Testing
- GSK3745417
- Where
- 10 sites in Canada, Germany and 3 more
- Volunteers
- 18 people
- Sponsor
- GlaxoSmithKline
Healthy
A Safety Study of Orally Administered BPM31510 in Healthy Subjects
This is an open-label, Phase I study of the bioavailability and safety of BPM31510 in healthy subjects dosed 2 or 3 times daily for 4 days, after an initial cohort of 6 subjects receiving a single dose (pre-study cohort).
- Trial name
- NCT02486055
- Testing
- BPM31510 Oral Nanosuspension 4%
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- BPGbio
Advanced Solid Tumors
A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-159642 in Participants With Advanced Solid Tumors
A FIH study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary anti-tumor activity of VVD-159642, a rat sarcoma viral oncogene-phosphatidylinositol 3-kinase alpha (RAS-PI3Kα)…
- Trial name
- NCT06804824
- Testing
- VVD-159642, Sotorasib, Trametinib
- Where
- 9 sites in United States, Australia
- Volunteers
- 220 people
- Sponsor
- Vividion Therapeutics, Inc.
Von Willebrand Disease, Type 3
A Study to Assess the Efficacy and Safety of Emicizumab in Participants With Type 3 Von Willebrand Disease
This is a Phase III, multicenter, open-label clinical study designed to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of emicizumab prophylaxis in participants aged 1 month and above, who have been…
- Trial name
- WILL-EMI (NCT06998524)
- Testing
- Emicizumab, von Willebrand Factor (VWF) Concentrates, Factor VIII (FVIII) Concentrates
- Where
- 29 sites in United States, Belgium and 12 more
- Volunteers
- 75 people
- Sponsor
- Hoffmann-La Roche
Non-alcoholic Fatty Liver Disease
6-week Safety and PD Study in Adults With NAFLD
IN THIS PHASE 2A, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, 3 ARM, PARALLEL- GROUP STUDY, SAFETY, TOLERABILITY, AND PHARMACODYNAMICS OF PF-06835919 ADMINISTERED ONCE DAILY FOR 6 WEEKS WILL BE ASSESSED IN ADULTS WITH…
- Trial name
- NCT03256526
- Testing
- PF-06835919 Low Dose, PF-06835919 High Dose
- Where
- 9 sites in United States
- Volunteers
- 53 people
- Sponsor
- Pfizer
Advanced Solid Tumor, Non-Hodgkin's Lymphoma
First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas
The ATR (ataxia-telangiectasia and Rad3 related protein) inhibitor BAY1895344 is developed for the treatment of patients with advanced solid tumors and lymphomas.
- Conditions
- Advanced Solid Tumor, Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma
- Trial name
- NCT03188965
- Testing
- Elimusertib (BAY1895344)
- Where
- 29 sites in United States, Canada and 5 more
- Volunteers
- 229 people
- Sponsor
- Bayer
Portal Hypertension
A Study to Investigate the Safety and Effect of the Study Drug (FE 204205) in Patients With Cirrhotic Portal Hypertension
The purpose of this trial is to investigate safety, tolerability, pharmacodynamics (PD), and pharmacokinetics (PK) after intravenous (IV) administration of FE 204205 in patients with cirrhotic portal hypertension.
- Trial name
- NCT02929407
- Testing
- FE 204205
- Where
- Spain
- Volunteers
- 4 people
- Sponsor
- Ferring Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.